DBD, US2536512021

Diebold Nixdorf reviews contract wins: DBD stock sits 33.30 percent below fair value

Published on 10/07/2026 at 05:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

DBD stock trades 28.90 percent below its USD 92.09 52-week high. Q2 revenue reached USD 927.60 million versus USD 923.07 million consensus.

DBD, US2536512021, Illustration mit AI erstellt.

Diebold Nixdorf (ISIN US2536512021) had its contract-win thesis reaffirmed on October 5, 2026, while DBD stock stood 33.30 percent below a fair value of USD 98.33. Simply Wall St said the valuation increased from USD 96.67 to USD 98.33, based on a USD 65.63 reference price.

Contract wins meet execution risk

The updated thesis points to network upgrades, regional tenders, multiyear European grocery contracts and new US deployments. It also highlights more than 200 cost actions and a link between those actions, EBITDA and free cash flow guidance.

For investors, the key issue is conversion rather than headline order volume. The source describes an order backlog of USD 814.00 million, making delivery timing and service mix central to the earnings case.

Revenue beats consensus in second quarter

MarketBeat reported that Diebold Nixdorf generated USD 927.60 million of revenue in the second quarter of 2026, above the USD 923.07 million consensus estimate. Quarterly earnings per share came in at USD 1.10, matching consensus.

Management set fiscal 2026 earnings-per-share guidance at USD 5.25 to USD 5.75. The latest operating data therefore combine a revenue comparison above expectations with a full-year profit range that leaves execution as the central variable.

DBD stock remains below its yearly high

DBD stock last stood at USD 65.48 on the NYSE on October 6, 2026 at 4:00 p.m. EDT. Its USD 54.48 to USD 92.09 52-week range places the quote 28.90 percent below the high, while market capitalization stood at USD 2.2 billion.

The further course of trading is shown by the continuously updated real-time quote of DBD stock.